DOCSLIB.ORG

Ethical Issues Regarding CRISPR-Mediated Genome Editing Zabta Khan Shinwari1,2*, Faouzia Tanveer1 and Ali Talha Khalil1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Ethical Issues Regarding CRISPR-mediated Genome Editing Zabta Khan Shinwari1,2*, Faouzia Tanveer1 and Ali Talha Khalil1 1Department of Biotechnology, Quaid-i-Azam University, Islamabad. 2Pakistan Academy of Sciences, Islamabad, Pakistan. *Correspondence: [email protected] htps://doi.org/10.21775/cimb.026.103 Abstract Introduction CRISPR/Cas9 has emerged as a simple, precise Te quest for introducing the site-specifc changes and most rapid genome editing technology. With in the DNA sequence began when DNA was frst a number of promising applications ranging from discovered. Progress in genome engineering tech- agriculture and environment to clinical therapeu- nologies began in 1990s now reaching to a highly tics, it is greatly transforming the feld of molecular advanced, easy, economical and sophisticated biology. However, there are certain ethical, moral method for editing genomes called CRISPR/Cas9. and safety concerns related to the atractive applica- CRISPR (Clustered Regularly Interspaced Palin- tions of this technique. Te most contentious issues dromic Repeats) technology does not arrive as a concerning human germline modifcations are the breakthrough technology for editing the genomes challenges to human safety and morality such as risk but other genome editing platforms like TALENS of unforeseen, undesirable efects in clinical appli- (Transcription Activator-Like Efector Nucleases) cations particularly to correct or prevent genetic and ZFN (Zinc Finger Nucleases) were in use for diseases, mater of informed consent and the risk of some time but have lost their popularity because exploitation for eugenics. Stringent regulations and of their complexity, expensiveness and time con- guidelines as well as worldwide debate and aware- sumption (Carroll and Charo, 2015; Doudna and ness are required to ensure responsible and wise use Charpentier, 2014; Hsu et al., 2014; Jinek et al., of CRISPR mediated genome editing technology. 2012). Te aforementioned techniques require Tere is a need for an extensive dialogue among protein engineering while CRISPR needs a guide scientists, ethicists, industrialists and policy makers RNA molecule that recognize the target sequence on its societal implications. Te opinion of diferent (Caplan et al., 2015). Te genome engineering tools elements of the society including the general public ofer promising advances in medicine, healthcare, as well as religious scholars is also critical. In coun- agriculture and food. CRISPR/Cas9 has brought a tries with existing legislative framework, it might revolution in the biological innovations. Tis tech- be appropriate to allow CRISPR-based research to nology can be used to treat the genetically inherited proceed with proper justifcation. However, much diseases by correcting the responsible mutation, anticipated future clinical applications must be analysing cancer progression and genetic rearrange- strictly regulated with newly established regula- ments (Doudna and Charpentier, 2014). Despite tions. the wide array of applications, ethicist raises serious Curr. Issues Mol. Biol. Vol. 26 104 | Shinwari et al. reservations about the CRISPR ability to easily Te present review discusses the ethical concerns modify the human germline cells, making these related to this new technology with special empha- changes transmitable to the progeny. sis on its possibilities and concerns on human CRISPR was initially discovered in the genome germline modifcations. It urges the need for an of E. coli by Japanese researchers in 1987 and extensive dialogue among scientists, ethicists, described as short direct repeats interspaced with industrialists and policy makers. Te opinion of dif- short sequences. Later on CRISPR was discov- ferent elements of the society including the general ered in many bacteria and archaea with a possible public as well as religious scholars is critical. role in gene regulation or DNA repair (Guy et al., 2004; Ishino et al., 1987; Makarova et al., 2002; Recent ethical debate: from where it Mojica et al., 2000). In 2005, it was discovered that started many spacer sequences that are accompanied with Te rapidly expanding scope of applications of CRISPRs were the derivatives of plasmid and viral CRISPR/Cas9 is incredible. It has provided a sequences (Bolotin et al., 2005). It was proposed number of possibilities in molecular biology by various research groups that CRISPR/Cas9 research, e.g. to turn of or on genes for studying has a possible role in adaptive immunity and this their function or to induce mutations in cells to proposition was confrmed later on in 2007 by study how and why cells become cancerous. It researchers working on Streptococcus thermophilus. can be used to alter genes in plants and animals In 2008, Brouns et al., in a study published in Sci- to create drought resistant crops or make police ence, showed that Cas proteins interfere with the dogs become more muscular. Ten comes a rather multiplication of a virus inside prokaryotes (E. contentious application to permanently modify the coli), while in the same year the DNA-targeting human genome to eliminate the disease-causing ability of CRISPR/Cas9 was established (Brouns et mutations or even enhance or introduce desired al., 2008; Marrafni and Sontheimer, 2008). (For characteristics in children by adding useful genes. a comprehensive history and mechanism which is Tough the idea of genetically modifed humans behind the scope of this review we recommend ‘Te and designer babies has been popular for a long new frontier of genome engineering with CRISPR/ time in both science and fction, CRISPR provided Cas9’ by Doudna et al., 2014.) a reasonable tool to turn this long cherished dream into a reality (le Page, 2015). Genomic changes made in the non-reproductive cells are not herit- Ethical issues regarding CRISPR able but if alterations are done to the germ cells technology (that develop into eggs, sperms or embryos), they Te rapidly growing technology of genome editing, can be passed to the ofspring. Te great accom- CRISPR/Cas9, is transforming the feld of molecu- plishment of CRISPR lies in the fact that it can be lar biology enabling scientists to make desired easily and precisely used in both reproductive and changes in DNA in a variety of organisms. Soon non-reproductive cells (Doudna, 2015). afer it was introduced in 2012, it has been quickly Until now, altering genes in humans was limited adopted due to ease of its use and simplicity. It is to gene therapy in which DNA modifcations were being considered for a variety of applications from inheritable. With accuracy and efciency of an agriculture to clinical therapeutics including human editor that could transfer the changes to the next germline alterations to correct genetic diseases generation, CRISPR has renewed the debate about (Carroll and Charo, 2015). Although the ethical human germline modifcations. With the advent debate on human genetic modifcations is not new of this technology, there was a sudden surge of (as mentioned previously), however, CRISPR/ genome editing experiments across the kingdom of Cas9-mediated genome editing has given it a new life, but mainly restricted to organisms other than edge. Owing to unpredictable and far reaching humans. Recently, there were also speculations that consequences associated with atractive applica- several scientists are secretly using this technology tions of this technology, a comprehensive dialogue on human embryos. In April 2015, research involv- is needed on its ethical and societal implications. ing CRISPR-based gene editing in human embryos Curr. Issues Mol. Biol. Vol. 26 CRISPR-mediated Genome Editing Ethical Issues | 105 appeared in an online journal ‘Protein and Cell’. Tis be edited. Tese made-to-order proteins may take study, done by a group of Chinese scientists (Liang years to make. In comparison, CRISPR simply et al., 2015) fanned the fames of ethical contro- requires a complementary RNA to bind the target versy on human germline alterations and triggered DNA taking only a few days to make. Tis is why a serious debate on issues such as how soon the CRISPR became popular as an efcient editing technology will be able to produce designer babies. technique among the scientists all over the world. Although the experiment was done on non-viable It is feared that with a gene editing technology like embryos meaning that they could not develop into CRISPR which can make changes in DNA efort- a live baby, it provided a proof of concept that, with lessly, the chances of things going wrong will also be litle tinkering of the CRISPR enzymes, the tech- larger. For example, the plants given characteristics nology might be someday successfully used on live like drought resistance or fast growth may become embryos (Krishan et al., 2015; Sharma and Scot, invasive weeds. Te most dreaded situation is that 2015). In general, apart from apprehensions related the technology may be used to produce a bio- to human genome, some environmental concerns weapon such as engineering an infectious pathogen have also been identifed as per CRISPR-mediated that infect humans or crops (Sarchet and Le Page, modifcations in plants such as crop improvement. 2015). It is very important to underline the regula- tory norms for the application of CRISPR. Safety Major concerns and security measures should be developed to con- trol any organism that can induce environmental Of-target mutations damage (Oye et al., 2014). Of-target mutations is one of the major concerns raised about the CRISPR/Cas9 genome engi-
Recommended publications
  • Efficient Genome Editing of an Extreme Thermophile, Thermus

    Efficient Genome Editing of an Extreme Thermophile, Thermus

    www.nature.com/scientificreports OPEN Efcient genome editing of an extreme thermophile, Thermus thermophilus, using a thermostable Cas9 variant Bjorn Thor Adalsteinsson1*, Thordis Kristjansdottir1,2, William Merre3, Alexandra Helleux4, Julia Dusaucy5, Mathilde Tourigny4, Olafur Fridjonsson1 & Gudmundur Oli Hreggvidsson1,2 Thermophilic organisms are extensively studied in industrial biotechnology, for exploration of the limits of life, and in other contexts. Their optimal growth at high temperatures presents a challenge for the development of genetic tools for their genome editing, since genetic markers and selection substrates are often thermolabile. We sought to develop a thermostable CRISPR-Cas9 based system for genome editing of thermophiles. We identifed CaldoCas9 and designed an associated guide RNA and showed that the pair have targetable nuclease activity in vitro at temperatures up to 65 °C. We performed a detailed characterization of the protospacer adjacent motif specifcity of CaldoCas9, which revealed a preference for 5′-NNNNGNMA. We constructed a plasmid vector for the delivery and use of the CaldoCas9 based genome editing system in the extreme thermophile Thermus thermophilus at 65 °C. Using the vector, we generated gene knock-out mutants of T. thermophilus, targeting genes on the bacterial chromosome and megaplasmid. Mutants were obtained at a frequency of about 90%. We demonstrated that the vector can be cured from mutants for a subsequent round of genome editing. CRISPR-Cas9 based genome editing has not been reported previously in the extreme thermophile T. thermophilus. These results may facilitate development of genome editing tools for other extreme thermophiles and to that end, the vector has been made available via the plasmid repository Addgene.
  • CRISPR/Cas9-Mediated Genome Editing Efficiently Creates Specific

    CRISPR/Cas9-Mediated Genome Editing Efficiently Creates Specific

    www.nature.com/scientificreports Correction: Author Correction OPEN CRISPR/Cas9-mediated genome editing efciently creates specifc mutations at multiple loci using one Received: 18 April 2017 Accepted: 3 July 2017 sgRNA in Brassica napus Published: xx xx xxxx Hong Yang1, Jia-Jing Wu1, Ting Tang1, Ke-De Liu 2 & Cheng Dai1 CRISPR/Cas9 is a valuable tool for both basic and applied research that has been widely applied to diferent plant species. Nonetheless, a systematical assessment of the efciency of this method is not available for the allotetraploid Brassica napus—an important oilseed crop. In this study, we examined the mutation efciency of the CRISPR/Cas9 method for 12 genes and also determined the pattern, specifcity and heritability of these gene modifcations in B. napus. The average mutation frequency for a single-gene targeted sgRNA in the T0 generation is 65.3%. For paralogous genes located in conserved regions that were targeted by sgRNAs, we observed mutation frequencies that ranged from 27.6% to 96.6%. Homozygotes were readily found in T0 plants. A total of 48.2% of the gene mutations, including homozygotes, bi-alleles, and heterozygotes were stably inherited as classic Mendelian alleles in the next generation (T1) without any new mutations or reversions. Moreover, no mutation was found in the putative of-target sites among the examined T0 plants. Collectively, our results demonstrate that CRISPR/Cas9 is an efcient tool for creating targeted genome modifcations at multiple loci that are stable and inheritable in B. napus. These fndings open many doors for biotechnological applications in oilseed crops.
  • CRISPR/Cas9: Tools and Applications for Eukaryotic Genome Editing

    CRISPR/Cas9: Tools and Applications for Eukaryotic Genome Editing

    CRISPR/Cas9: Tools and Applications for Eukaryotic Genome Editing Fei Ann Ran Broad Institute Cambridge, Massachusetts [email protected] I will provide some background on the CRISPR/Cas9 technology, some of the rationale for how we came to develop and use this tool, and I will address immediate questions concerning the specificity of the technology. I will also discuss some of the more interest- ing applications. Figure 1 reflects how the cost of DNA sequencing has decreased dramatically over the past two decades due to technological progress. As a result, there has been an explo- sion of data, not only in the sequences of different species, but in sequence differences between individuals within species, between cell types and between diseased and healthy cells. It suffices to say that this is an exciting time to be working in the field of genome engineering. Genome Engineering Typically, genome engineering is achieved by leveraging the cell’s own repair machinery. This can come from the error-prone NHEJ pathway that leads to insertion/deletion (in- del) mutations, which can be used to knock out genes, or, alternatively, we can supply a repair template to overwrite the site of a double-stranded break (DSB) for more-precise genome engineering via the HDR pathway (Figure 2). Figure 1. Advances in DNA-sequencing technologies. (Stratton MR et al., 2009) When we started working on CRISPR/Cas technology1, several well developed tools were already being used—and still are being used—to achieve impressive results in bio- technology, medicine, agriculture, and other fields. At the outset, we were interested in developing an alternative technology to make cloning easier at lower cost with greater scalability.
  • Human Challenge Trials for Vaccine Development: Regulatory Considerations

    Human Challenge Trials for Vaccine Development: Regulatory Considerations

    POST ECBS Version ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 Human Challenge Trials for Vaccine Development: regulatory considerations © World Health Organization 2016 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.
  • Informed Consent and Refusal

    Informed Consent and Refusal

    CHAPTER 3 Informed Consent and Refusal Evolution of the doctrine of informed consent Elements of informed consent and refusal The nature of informed consent Exceptions to the consent requirement Mrs. Stack is a 67- year- old woman admitted with rectal bleeding, chronic renal in- sufficiency, diabetes, and blindness. On admission, she was alert and capacitated. Two weeks later, she suffered a cardiopulmonary arrest, was resuscitated and intu- bated, and was transferred to the medical intensive care unit (MICU) in an unrespon- sive and unstable state. Consent for emergency dialysis was obtained from her son, who is also her health care agent. Dialysis was repeated two days later. During the past several years, Mrs. Stack has consistently stated to her family and her primary care doctor that she would never want to be on chronic dialysis and she has refused it numerous times when it was recommended. The physician, who has known and treated Mrs. Stack for many years, also treated her daughter who had been on chronic dialysis for some time and had died after suffering a heart attack. According to the physician and the patient’s family, Mrs. Stack’s refusal of dialysis has been based on her conviction that her daughter died as a result of the dialysis treatments. Mrs. Stack’s mental status has cleared considerably and, despite the ventilator, she is able to communicate nonverbally. Although she appears to understand the benefits of dialysis and the consequences of refusing it, including deterioration and eventual death, she has consistently and vehemently refused further treatments. Her capacity to make this decision is not now in question.
  • The Implications of Religious Beliefs on Medical and Patient Care

    The Implications of Religious Beliefs on Medical and Patient Care

    University of Pennsylvania ScholarlyCommons Master of Science in Organizational Dynamics Theses Organizational Dynamics Programs 11-14-2011 The Implications of Religious Beliefs on Medical and Patient Care Dana I. Al Husseini University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/od_theses_msod Al Husseini, Dana I., "The Implications of Religious Beliefs on Medical and Patient Care" (2011). Master of Science in Organizational Dynamics Theses. 46. https://repository.upenn.edu/od_theses_msod/46 Submitted to the Program of Organizational Dynamics in the Graduate Division of the School of Arts and Sciences in Partial Fulfillment of the Requirements for the Degree of Master of Science in Organizational Dynamics at the University of Pennsylvania Advisor: Adrian Tschoegl This paper is posted at ScholarlyCommons. https://repository.upenn.edu/od_theses_msod/46 For more information, please contact [email protected]. The Implications of Religious Beliefs on Medical and Patient Care Abstract Throughout history and to this date in a continuously globalized world, monotheistic religions and medicine have caused numerous acrimonious debates especially in crucial moments of life and death. Medical and nursing staff working with patients from different religions in any country in the world must adhere to and respect those patients’ faiths and be aware of them to provide better patient care and in worst case scenarios, avoid litigation. Furthermore, this paper should not to be treated as an encyclopedic reference; it is merely a general overview into the three monotheistic faiths to alert professional healthcare staff of the possibility of a religious implication even if it contradicts their own concerns and points of views.
  • Informed Consent

    Informed Consent

    Christine Grady Department of Bioethics NIH Clinical Center The views expressed here are mine and do not necessarily represent those of the CC, NIH, or Department of Health and Human Services Informed consent is the bedrock principle on which most of modern research ethics rest…This was at the heart of the crucial ethical provision stated in the first words of the Nuremberg Code, and it remains equally compelling a half century later. Menikoff J, Camb Quarterly 2004 p 342 Authorization of an activity based on understanding what the activity entails. A legal, regulatory, and ethical requirement in health care and in most research with human subjects A process of reasoned decision making (not a form or an episode) One aspect of conducting ethical clinical research “Every human being of adult years and sound mind has a right to determine what will be done with his body… Justice Cardozo, 1914 Respect for autonomy or for an individual’s capacity and right to define own goals and make choices consistent with those goals. Well entrenched in American values, jurisprudence, medical practice, and clinical research. “Informed consent is rooted in the fundamental recognition…that adults are entitled to accept or reject health care interventions on the basis of their own personal values and in furtherance of their own personal goals” Presidents Commission for the study of ethical problems…1982 Informed consent in medical practice …informed consent in clinical practice is frequently inadequate… Physicians receive little training… Misunderstand requirements and legal standards… Time pressures and competing demands… Patient comprehension is often poor… Recent studies have demonstrated improvement in patient understanding of risks after communication interventions Schenker et al 2010; Matiasek et al.
  • Informed Consent for Participation in Personal Training

    Informed Consent for Participation in Personal Training

    PRINCETON UNIVERSITY Personal Training INFORMED CONSENT FOR PARTICIPATION IN PERSONAL TRAINING Name: ________________________ 1. Purpose and Explanation of Procedure I desire to participate voluntarily in an acceptable plan of exercise conditioning. I also desire to be placed in program activities which are recommended to me for improvement of my general health and well-being in which I will be given exact instructions regarding the amount and kind of exercise I should do. Professionally trained personnel will provide leadership to direct my activities, monitor my performance and otherwise evaluate my effort. Depending upon my health status, I may or may not be required to have my heart rate evaluated during these sessions and/or regulate my exercise within desired limits. I understand that I am expected to follow staff instructions with regard to the proper performance of each exercise. I have been advised and understand it is recommended that I obtain a medical examination by a physician before I participate in this program. The medical examination is highly suggested in order to identify conditions which may preclude participation. If I am taking prescribed medications, I have already so informed the program staff and further agree to inform them promptly of any changes which my doctor or I may make with regard to such use. I have been informed that during my participation in exercise, I will be asked to complete the physical activities unless such symptoms as fatigue, shortness of breath, chest discomfort or similar occurrences appear. At that point, I have been advised it is my complete right and responsibility to decrease or stop exercising and that it is my obligation to inform the program personnel of my symptoms.
  • TWU IRB Reference Sheet for Recruitment and Informed Consent

    TWU IRB Reference Sheet for Recruitment and Informed Consent

    TWU IRB Reference Sheet for Recruitment and Informed Consent RECRUITMENT Recruitment Materials (flyers, email scripts, social media posts, etc.) • Items that are required: • State that research will be conducted • State that participation is voluntary • If the internet/email is used for participation, include the following statement: “There is a potential risk of loss of confidentiality in all email, downloading, electronic meetings, and internet transactions.” • Items that are NOT required, but recommended: • PI’s contact information (email is recommended over cell phone #, but both are okay) • Location/site of the study • Study title • Brief description of the study • If using a TWU logo, TWU marketing is asking that you use the new logo • Main eligibility requirements • Benefits for participation • Total time commitment • If your scripts will vary across different platforms (email script, social media post, phone script, etc.), make sure you attach all appropriate scripts. If you are using the same script across all platforms, state so. • Make sure the information you include is consistent with the information you provide in the application and consent form. • Remember, it is okay to leave out details that are subject to change (e.g., study or session dates, gift card vendors). It is very possible that your study will not start when you want it to. If you leave out actual dates, you will not need to submit a modification request to change it later. The same thing goes with gift cards. If your study is funded, you may work with ORSP to get gift cards. You may need 40 $5 gift cards, but they do not have 40 from the same vendor.
  • Genetic Modification for Agriculture—Proposed Revision of GMO Regulation in Australia

    Genetic Modification for Agriculture—Proposed Revision of GMO Regulation in Australia

    plants Opinion Genetic Modification for Agriculture—Proposed Revision of GMO Regulation in Australia Robert Redden RJR Agriculture Consultants, 62 Schier Drive, Horsham 340, Australia; [email protected] Abstract: Genetic engineering (GM) of crops, modified with DNA transfer between species, has been highly regulated for over two decades. Now, genome editing (GE) enables a range of DNA alterations, from single base pair changes to precise gene insertion with site-directed nucleases (SDNs). Past regulations, established according to the precautionary principle of avoiding potential risks to human health and the environment, are predicated on fears fanned by well-funded and emotional anti-GM campaigns. These fears ignore the safety record of GM crops over the last 25 years and the benefits of GM to crop productivity, disease and pest resistance, and the environment. GE is now superseding GM, and public education is needed about its benefits and its potential to meet the challenges of climate change for crops. World population will exceed 9 billion by 2050, and world CO2 levels are now over 400 ppm in contrast with a pre-industrial 280 ppm, leading to a projected 1.5 ◦C global warming by 2050, with more stressful crop environments. The required abiotic and biotic stress tolerances can be introgressed from crop wild relatives (CWR) into domestic crops via GE. Restrictive regulations need to be lifted to facilitate GE technologies for sustainable agriculture in Australia and the world. Keywords: genetic engineering; genome editing; regulation; climate change; precautionary principle Citation: Redden, R. Genetic Modification for Agriculture—Proposed Revision of 1. Introduction GMO Regulation in Australia.
  • The Informed Consent Process Research Network What Is Informed Consent?

    The Informed Consent Process Research Network What Is Informed Consent?

    Dietetics Practice Based The Informed Consent Process Research Network What is informed consent? Informed consent is a process of information exchange about the research including reviewing eligibility or recruitment materials with the subject, reviewing the informed consent document, answering questions, and checking for subject understanding. Usually, but not always, at the end of this process the informed consent is documented via a signature from the subject. One of the main goals of the informed consent process is to help the potential subject make a risk-benefit ratio assessment regarding their study participation. Explain eligibility Provide relevant information about project goals and requirements Assess understanding Answer questions Obtain consent Document (if necessary) The Informed Consent Document—What are the required elements? An Informed Consent Document should include all of the following elements: • Research Statement—be clear that the project is research, also include the purpose, duration, and required procedures • Risks and discomforts • Benefits (remember that payment or compensation is not a benefit) • Alternatives—What are other options to the subject besides taking part in the research (including not taking part in the research as an option) • Confidentiality and limits thereof (remember that regulatory agencies may look at the records) • Compensation for study participation • Contact person • Voluntary Refusal and Right to withdraw—subject may stop participation at any time and not lose any benefits they are
  • RNA-Guided CRISPR-Cas Technologies for Genome-Scale Investigation of Disease Processes Sean E Humphrey and Andrea L Kasinski*

    RNA-Guided CRISPR-Cas Technologies for Genome-Scale Investigation of Disease Processes Sean E Humphrey and Andrea L Kasinski*

    Humphrey and Kasinski Journal of Hematology & Oncology (2015) 8:31 DOI 10.1186/s13045-015-0127-3 JOURNAL OF HEMATOLOGY & ONCOLOGY REVIEW Open Access RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes Sean E Humphrey and Andrea L Kasinski* Abstract From its discovery as an adaptive bacterial and archaea immune system, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system has quickly been developed into a powerful and groundbreaking programmable nuclease technology for the global and precise editing of the genome in cells. This system allows for comprehensive unbiased functional studies and is already advancing the field by revealing genes that have previously unknown roles in disease processes. In this review, we examine and compare recently developed CRISPR-Cas platforms for global genome editing and examine the advancements these platforms have made in guide RNA design, guide RNA/Cas9 interaction, on-target specificity, and target sequence selection. We also explore some of the exciting therapeutic potentials of the CRISPR-Cas technology as well as some of the innovative new uses of this technology beyond genome editing. Introduction from a region of the host genome adjacent to the Clustered regularly interspaced short palindromic repeats CRISPR region is directed to the invading DNA in a (CRISPR)-Cas systems are adaptive immune systems used sequence-dependent manner via the crRNA. Once by many bacteria and archaea to fight off foreign DNA in bound to the foreign DNA, Cas9 introduces a double- the form of bacterial phages and/or plasmids [1-5]. Al- stranded break in the foreign DNA [11-13].